Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 3

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 3
---
 Nasdaq rules and such price
equals or exceeds the sum of (a) the applicable “Minimum Price” per share under Nasdaq Listing Rule 5635(d) plus (b) $0.125
per whole share of common stock underlying the Warrants or (ii) the offering is a discounted offering where the pricing and discount (including
attributing a value of $0.125 per whole share underlying the Warrants) meet the pricing requirements under Nasdaq’s rules.

We are also offering pre-funded warrants (the
“Pre-Funded Warrants”), together with accompanying Series A-1 Warrants to purchase up to 2,036,659 shares of common stock
and Series A-2 Warrants to purchase up to 2,036,659 shares of common stock, to those purchasers whose purchase of shares of
common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation
of this offering. Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share.
Each Pre-Funded Warrant is being issued together with the same Warrants described above being issued with each share of common stock.
The combined assumed public offering price for each such Pre-Funded Warrant, together with accompanying the Warrants, is $2.4549, which
is the combined public offering price per common share and accompanying Warrants (equal to the last reported sale price of our common
stock on The Nasdaq Capital Market on July 2, 2025 minus $0.0001). Each Pre-Funded Warrant will be exercisable upon issuance and may be
exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants and accompanying Warrants are
immediately separable and will be issued separately in this offering. For each Pre-Funded Warrant we sell, the number of shares of common
stock we sell in this offering will be decreased on a one-for-one basis.

Pursuant to the registration statement related
to this prospectus, we are also registering the offer and sale of the shares of common stock issuable upon exercise of the Warrants and
the Pre-Funded Warrants and the placement agent warrants (the